Dharmendra Kumar Aggarwal v. Govt. Of Nct Of Delhi Through The Secretary & Anr.

When a deadly pandemic sweeps across a nation and the only drug that can save lives is suddenly unavailable, the legal system becomes an unexpected lifeline. The case of Dharmendra Kumar Aggarwal vs Govt. of NCT of Delhi is not just a story about a drug shortage—it is a powerful example of how courts can step in to demand accountability from both pharmaceutical giants and government bodies when public health hangs in the balance. For founders, healthcare leaders, and IP professionals, this case offers a critical lesson: in moments of crisis, transparency is not optional, and silence can be legally costly.

The dispute arose during the devastating second wave of the COVID-19 pandemic in India, when Delhi's hospitals were overwhelmed and families desperately searched for the drug Tocilizumab 400 MG, marketed under the brand name Actemra. This drug had emerged as a critical treatment option for severe COVID-19 patients, but its availability became a matter of life and death. The petitioner, Dharmendra Kumar Aggarwal, approached the court seeking intervention to address the acute shortage of this medication in Delhi. The central question was straightforward yet profound: how could the court ensure that this essential drug reached the patients who needed it most? The respondent was the Government of NCT of Delhi, but the real focus of the inquiry quickly shifted to Roche India, the company responsible for manufacturing and supplying Tocilizumab in the Indian market.

Roche India presented a sobering picture to the court. The company submitted that global demand for Tocilizumab had surged far beyond their current manufacturing capabilities, making it impossible to meet the skyrocketing needs across multiple countries simultaneously. While Roche acknowledged the severity of the crisis and mentioned that they had entered into partnerships with other entities to scale up production, they offered no concrete assurance about when or how much additional supply would reach India. This vague response created a legal friction: the petitioner and the court needed definitive answers about supply timelines, manufacturing capacity, and potential alternatives, but Roche's submissions were characterized by uncertainty and lack of commitment. The gap between what the public needed and what the company was willing to guarantee became the central battleground of this case.

The court recognized that this was not merely a commercial dispute but a matter of public health urgency. It issued detailed directions to both Roche India and the Union of India, requiring them to file comprehensive affidavits addressing several critical aspects: the current status of the supply chain for Tocilizumab, detailed information about the patent status of the drug, and the availability of potential alternatives that could be used in its place. By demanding this level of transparency, the court ensured that the decision-making process around drug availability would be informed by accurate, verifiable data rather than corporate assurances alone. The outcome was mixed—while the court did not impose immediate supply mandates, it successfully compelled both the pharmaceutical company and the government to come forward with full disclosure, creating a framework for accountability during an unprecedented health emergency.

For founders, startup leaders, and IP professionals operating in the pharmaceutical and healthcare sectors, this case delivers an unmistakable message: in public health crises, judicial intervention can and will be used to compel transparency. If your business holds a critical position in a drug supply chain, you must be prepared to provide clear, honest, and comprehensive information about your manufacturing capacity, patent holdings, and supply commitments. Vague promises and corporate hedging will not satisfy the courts when lives are at stake. Build transparency into your crisis response plans from day one, maintain open communication channels with regulatory bodies, and always have contingency plans for scaling production. In the intersection of intellectual property and public health, the law demands nothing less than full disclosure.